Rock Springs Capital — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+7 more
A portfolio biopharmaceutical company translating basic medical research breakthroughs from leading universities into novel therapeutic medicines.
BiotechDeep TechMedical DevicesCambridge, GB
Richard Butt(Chief Scientific Officer)inSanjay Aggarwal(Chief Medical Officer)in
Co-investorsPatient Square CapitalAlbionVC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.